Yevgeniy Vinogradskiy1, Richard Castillo2, Edward Castillo3, Leah Schubert4, Bernard L Jones4, Austin Faught5, Laurie E Gaspar4, Jennifer Kwak6, Daniel W Bowles7, Timothy Waxweiler4, Jingjing M Dougherty8, Dexiang Gao9, Craig Stevens3, Moyed Miften4, Brian Kavanagh4, Inga Grills3, Chad G Rusthoven4, Thomas Guerrero3. 1. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: yevgeniy.vinogradskiy@jefferson.edu. 2. Department of Radiation Oncology, Emory University, Atlanta, Georgia. 3. Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan. 4. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. 5. Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Radiology, University of Colorado School of Medicine, Aurora, Colorado. 7. Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado; Rocky Mountain Regional VA Medical Center, Aurora, Colorado. 8. Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida. 9. Departments of Pediatrics and Biostatistics and Informatics, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
PURPOSE: Radiation pneumonitis remains a major limitation in the radiation therapy treatment of patients with lung cancer. Functional avoidance radiation therapy uses functional imaging to reduce pulmonary toxic effects by designing radiation therapy plans that reduce doses to functional regions of the lung. Lung functional imaging has been developed that uses 4-dimensional computed tomography (4DCT) imaging to calculate 4DCT-based lung ventilation (4DCT-ventilation). A phase 2 multicenter study was initiated to evaluate 4DCT-ventilation functional avoidance radiation therapy. The study hypothesis was that functional avoidance radiation therapy could reduce the rate of grade ≥2 radiation pneumonitis to 12% compared with a 25% historical rate, with the trial being positive if ≤16.4% of patients experienced grade ≥2 pneumonitis. METHODS AND MATERIALS: Lung cancer patients receiving curative-intent radiation therapy (prescription doses of 45-75 Gy) and chemotherapy were accrued. Patient 4DCT scans were used to generate 4DCT-ventilation images. The 4DCT-ventilation images were used to generate functional avoidance plans that reduced doses to functional portions of the lung while delivering the prescribed tumor dose. Pneumonitis was evaluated by a clinician at 3, 6, and 12 months after radiation therapy. RESULTS: Sixty-seven evaluable patients were accrued between April 2015 and December 2019. The median prescription dose was 60 Gy (range, 45-66 Gy) delivered in 30 fractions (range, 15-33 fractions). The average reduction in the functional volume of lung receiving ≥20 Gy with functional avoidance was 3.5% (range, 0%-12.8%). The median follow-up was 312 days. The rate of grade ≥2 radiation pneumonitis was 10 of 67 patients (14.9%; 95% upper CI, 24.0%), meeting the phase 2 criteria. CONCLUSIONS: 4DCT-ventilation offers an imaging modality that is convenient and provides functional imaging without an extra procedure necessary. This first report of a multicenter study of 4DCT-ventilation functional avoidance radiation therapy provided data showing that the trial met phase 2 criteria and that evaluation in a phase 3 study is warranted.
PURPOSE: Radiation pneumonitis remains a major limitation in the radiation therapy treatment of patients with lung cancer. Functional avoidance radiation therapy uses functional imaging to reduce pulmonary toxic effects by designing radiation therapy plans that reduce doses to functional regions of the lung. Lung functional imaging has been developed that uses 4-dimensional computed tomography (4DCT) imaging to calculate 4DCT-based lung ventilation (4DCT-ventilation). A phase 2 multicenter study was initiated to evaluate 4DCT-ventilation functional avoidance radiation therapy. The study hypothesis was that functional avoidance radiation therapy could reduce the rate of grade ≥2 radiation pneumonitis to 12% compared with a 25% historical rate, with the trial being positive if ≤16.4% of patients experienced grade ≥2 pneumonitis. METHODS AND MATERIALS: Lung cancer patients receiving curative-intent radiation therapy (prescription doses of 45-75 Gy) and chemotherapy were accrued. Patient 4DCT scans were used to generate 4DCT-ventilation images. The 4DCT-ventilation images were used to generate functional avoidance plans that reduced doses to functional portions of the lung while delivering the prescribed tumor dose. Pneumonitis was evaluated by a clinician at 3, 6, and 12 months after radiation therapy. RESULTS: Sixty-seven evaluable patients were accrued between April 2015 and December 2019. The median prescription dose was 60 Gy (range, 45-66 Gy) delivered in 30 fractions (range, 15-33 fractions). The average reduction in the functional volume of lung receiving ≥20 Gy with functional avoidance was 3.5% (range, 0%-12.8%). The median follow-up was 312 days. The rate of grade ≥2 radiation pneumonitis was 10 of 67 patients (14.9%; 95% upper CI, 24.0%), meeting the phase 2 criteria. CONCLUSIONS: 4DCT-ventilation offers an imaging modality that is convenient and provides functional imaging without an extra procedure necessary. This first report of a multicenter study of 4DCT-ventilation functional avoidance radiation therapy provided data showing that the trial met phase 2 criteria and that evaluation in a phase 3 study is warranted.
Authors: Zhi-Qin Jiang; Kunyu Yang; Ritsuko Komaki; Xiong Wei; Susan L Tucker; Yan Zhuang; Mary K Martel; Sastray Vedam; Peter Balter; Guangying Zhu; Daniel Gomez; Charles Lu; Radhe Mohan; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-11 Impact factor: 7.038
Authors: John Kipritidis; Bilal A Tahir; Guillaume Cazoulat; Michael S Hofman; Shankar Siva; Jason Callahan; Nicholas Hardcastle; Tokihiro Yamamoto; Gary E Christensen; Joseph M Reinhardt; Noriyuki Kadoya; Taylor J Patton; Sarah E Gerard; Isabella Duarte; Ben Archibald-Heeren; Mikel Byrne; Rick Sims; Scott Ramsay; Jeremy T Booth; Enid Eslick; Fiona Hegi-Johnson; Henry C Woodruff; Rob H Ireland; Jim M Wild; Jing Cai; John E Bayouth; Kristy Brock; Paul J Keall Journal: Med Phys Date: 2019-02-01 Impact factor: 4.071
Authors: Richard Castillo; Edward Castillo; Matthew McCurdy; Daniel R Gomez; Alec M Block; Derek Bergsma; Sarah Joy; Thomas Guerrero Journal: Phys Med Biol Date: 2012-03-13 Impact factor: 3.609
Authors: Jaden D Evans; Daniel R Gomez; Arya Amini; Neal Rebueno; Pamela K Allen; Mary K Martel; Justin M Rineer; Kie Kian Ang; Sarah McAvoy; James D Cox; Ritsuko Komaki; James W Welsh Journal: Radiother Oncol Date: 2013-02-28 Impact factor: 6.280
Authors: Susan L Tucker; Hekun Jin; Xiong Wei; Shulian Wang; Mary K Martel; Ritsuko Komaki; H Helen Liu; Radhe Mohan; Yuhchyau Chen; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-14 Impact factor: 7.038
Authors: Brian P Yaremko; Thomas M Guerrero; Josue Noyola-Martinez; Rudy Guerra; David G Lege; Linda T Nguyen; Peter A Balter; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-29 Impact factor: 7.038
Authors: Greg A Durm; Salma K Jabbour; Sandra K Althouse; Ziyue Liu; Ahad A Sadiq; Robin T Zon; Shadia I Jalal; Goetz H Kloecker; Michael J Williamson; Karen L Reckamp; Robert M Langdon; Ebenezer A Kio; Ryan D Gentzler; Bamidele A Adesunloye; Wael A Harb; Radhika V Walling; Michael L Titzer; Nasser H Hanna Journal: Cancer Date: 2020-07-22 Impact factor: 6.860
Authors: Yevgeniy Vinogradskiy; Phillip J Koo; Richard Castillo; Edward Castillo; Thomas Guerrero; Laurie E Gaspar; Moyed Miften; Brian D Kavanagh Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: Esther M Vicente; Arezoo Modiri; John Kipritidis; Kun-Chang Yu; Kai Sun; Jochen Cammin; Arun Gopal; Jingzhu Xu; Sina Mossahebi; Aaron Hagan; Yulong Yan; Daniel Rockwell Owen; Pranshu Mohindra; Martha M Matuszak; Robert D Timmerman; Amit Sawant Journal: Int J Radiat Oncol Biol Phys Date: 2022-03-09 Impact factor: 8.013